Explore expert insights and educational material on CAR T-cell therapy and access up-to-date information on NHL. The Kite Medical Hub is a non-promotional website intended for healthcare professionals in the UK and Ireland, designed, built and funded by Kite, a Gilead Company.
Welcome to eRMM Tool an interactive training tool on the management of cytokine release syndrome and neurotoxicity in your YESCARTA® (axicabtagene ciloleucel) CAR T patients.
A CAR T patient avatar will take you on their treatment journey: from preparing your delivery centre, handling and administering treatment to managing any side effects promptly.
Upon completing a quiz at the end, you will be awarded an accredited CPD Certificate.
Additional monitoring required.
Latest podcastSee more podcasts
Autologous stem cell transplantation: Selecting patients and managing risk
Dr Keith Wilson, Consultant Haematologist at Cardiff and Vale University Health Board, discusses how patients with diffuse large B-cell lymphoma are selected for autologous stem cell transplantation and how they are managed thereafter, including the importance of considering CAR T as a 3rd-line therapy at an early stage.
Latest eventsSee more events
CAR T, chimeric antigen receptor T-cell; GIO-Med, Gilead Immuno-Oncology Medical Education; NHL, non-Hodgkin lymphoma; UK, United Kingdom.
You are now leaving the Kite a Gilead Company, non-promotional website.
You are being directed to